Reports & Databases
Subscribe to
our newsletters!
Showing 1–20 of 50 results
- September of 2020This Target Pipeline List provides an overview of inhibitors of the CD47-SIRPα pathway in development as a next generation immuno-oncology treatment of cancer€ 200.00
- August of 2020This report describes the landscape of industry-driven approaches to discover and develop recombinant therapeutic antibodies against SARS-CoV-2 for treatment of COVID-19€ 200.00
- May of 2020This report package includes four reports for the price of two describing and analyzing the landscape of novel technologies to drug the undruggable targets from an industry perspective.
€ 8250.00€ 4125.00 - May of 2020Report with a landscape analysis of Targeted Protein Degradation (TPD) technologies and of discovery and development of TPD drug candidates from an industry perspective as of May 2020€ 2050.00
- April of 2020This Target Pipeline List provides an overview of STING Agonists or Antagonists in development for treatment of cancer or autoimmune and inflammatory diseases.€ 150.00
- March of 2020Report about COVID-19 Vaccines in Development with landscape analysis of industry-driven R&D projects of vaccines for prevention of COVID-19 as of March 27, 2020€ 100.00
- March of 2020Compilation of the global sales data of branded originator recombinant therapeutic proteins and antibodies and of selected biosimilars in the calendar year 2019€ 90.00
- March of 2020Report about SARS-CoV-2 Treatment & Prevention Approaches undertaken by industry to evaluate existing and discover novel treatments and vaccines for COVID-19.€ 150.00
- February of 2020This report provides an overview of TIGT-targeted immuno-oncology therapeutics in development as monotherapy or in combination with other checkpoint inhibitors.€ 100.00
- February of 2020Online database for annual global sales since 2007 of recombinant therapeutic antibodies & proteins in regulated markets (branded originator products, increasingly also for biosimilars)€ 200.00
- December of 2019Competitive intelligence report about next wave biosimilar antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More as of December 2019€ 600.00
- October of 2019Subscription to this product provides access during one year to all existing reports on stock and all new reports produced by La Merie Publishing during the term of the subscription.€ 4000.00
- October of 2019This report about KRAS Inhibitors evaluates the landscape of investigational small molecules, antibodies, cell therapeutics and vaccines targeting KRAS for treatment of cancer€ 250.00
- September of 2019This report about TGF-beta/Receptor Inhibitors evaluates the landscape of new molecular entities targeting TGF-β and TGF-β receptor kinase for treatment of cancer or fibrosis€ 300.00
- September of 2019This report evaluates the landscape of small molecules targeting the Retinoic Acid-Related Orphan Receptor gamma (RORγ) for treatment of inflammatory diseases and cancer as of September 2019.€ 250.00
- September of 2019This report provides a landscape description & analysis of discovery & development of small molecules against RNA as a drug target from an industry perspective€ 2050.00
- June of 2019Package of two reports with in depth analysis of T-cell and NK cell engaging bispecific antibodies and competitor analysis of 271 unique bispecific antibody-based constructs
€ 3150.00€ 2500.00 - July of 2019This Target Pipeline List provides an overview of selective and bispecific CD137 receptor agonists in development for treatment of solid tumors.€ 150.00
- July of 2019This Target Pipeline List provides an overview of FGF21 receptor agonists in development for treatment of obesity, diabetes and non-alcoholic steatohepatitis (NASH).€ 50.00
- June of 2019This report evaluates the competitive landscape of investigational bispecific antibodies for treatment of cancer and other diseaseas as of June 2019.€ 800.00
